Powered by: Motilal Oswal
5/12/2022 3:25:17 PM | Source: Motilal Oswal Financial Services Ltd
Neutral GSK Pharma Ltd For Target Rs.1,420 - Motilal Oswal Financial Services
News By Tags | #872 #557 #4315 #642 #1302
Neutral GSK Pharma Ltd For Target Rs.1,420 - Motilal Oswal Financial Services

Vaccines remain a drag on the overall 2QFY23 performance

* GSK Pharma (GLXO) delivered an in-line performance in 2QFY23. The healthy progress in general medicines and specialty business segments was offset by reduced traction in the vaccines business.

* We maintain our earnings estimates for FY23/FY24. We value GLXO at 35x 12M forward earnings to arrive at our TP of INR1,420. We expect an 8% earnings CAGR over FY22-24 fueled by 5% sales CAGR and 130bp margin expansion.

* GLXO’s focus on core brands has yielded better-than-industry growth in its focus market of certain therapies. However, we maintain our Neutral rating on the stock due to limited upside (+7%) from the current levels.

Product mix benefit offset by higher promotional spends on a YoY basis

* GLXO’s revenue declined 2% YoY to INR9.2b (v/s est. of INR9.1b) in 2QFY23.

* Gross margin (GM) expanded 180bp YoY to 60.2% led by product mix.

* EBITDA margin improved marginally by 40bp YoY to 28% due to lower employee cost (-160bp YoY as a % of sales) offset by higher other expenses (+300bp YoY as a % of sales).

* EBITDA was flat YoY to INR2.6b (v/s est. of INR2.5b) during the quarter.

* Adj. PAT was stable YoY to INR1.9b for the quarter (our est. INR 1.9b).

* In 1HFY23, GLXO’s revenue was flat YoY while EBITDA/PAT grew 4% YoY each

Key result highlights

* The quarterly growth underlines the strong momentum across focus brands.

* During 1HFY23, GLXO launched its parent’s innovative product – Trelegy Ellipta – the first single-inhaler triple therapy (SITT), in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime for patients aged 18 years and above.

* Secondary sales data from AIOCD indicates that Dermatology /Anti-Infective (~30%/~27% of overall sales) saw a ~20%/22% YoY growth in 2QFY23, respectively, driving the outperformance against IPM.

* T-Bact/ Neosporin in Derma therapy saw 32%/20% YoY growth, respectively. Augmentin grew 22% YoY in 2QFY23 according to AIOCD.

* Pain therapy (11% of sales) grew 11% YoY and Hormones therapy (8% of sales) rose 4% YoY during the quarter.

* Vaccines (~10% of sales) declined 27% YoY with Infanrix Hexa in vaccines exhibiting a modest 4 YoY growth in 2QFY23.

* GLXO delivered a modest volume growth of 1% and price hike of 6.3% YoY for the 12-month ending Sep’22 aided by a 1.8% growth from new launches.

 

 

To Read Complete Report & Disclaimer Click Here

 

For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html SEBI Registration number is INH000000412

 

Above views are of the author and not of the website kindly read disclaimer

 

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here